Natera, Inc. (NASDAQ:NTRA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Natera, Inc. has received an average consensus rating of "Moderate Buy" from twenty research firms, with two sell ratings, one hold, sixteen buy ratings, and one strong buy rating.
• The company reported a 32.2% year-over-year revenue increase for the latest quarter but missed earnings expectations with an EPS of ($0.74).
• Insider transactions include CEO Steven Chapman selling 14,083 shares, reducing his ownership by 8.38%, and CFO Michael Brophy selling 3,045 shares, highlighting significant insider activity.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $197.5882.

NTRA has been the topic of several recent research reports. Piper Sandler reiterated an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Canaccord Genuity Group reissued a "buy" rating and set a $200.00 price objective on shares of Natera in a report on Tuesday, October 14th. Morgan Stanley reiterated an "overweight" rating and set a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Natera in a research note on Wednesday, October 8th. Finally, Stephens reaffirmed an "overweight" rating and issued a $183.00 price objective on shares of Natera in a research note on Friday, August 15th.

Natera Stock Down 1.3%

Shares of NTRA stock opened at $192.51 on Friday. The company has a market capitalization of $26.42 billion, a P/E ratio of -100.79 and a beta of 1.74. Natera has a 12-month low of $117.27 and a 12-month high of $198.99. The firm has a 50-day moving average price of $171.29 and a 200 day moving average price of $160.18.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter in the previous year, the company posted ($0.30) EPS. Natera's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, research analysts expect that Natera will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 14,083 shares of Natera stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the completion of the sale, the chief executive officer directly owned 154,072 shares of the company's stock, valued at $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Burkes Brophy sold 3,045 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the transaction, the chief financial officer directly owned 65,430 shares in the company, valued at $8,990,082. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,446 shares of company stock valued at $11,207,899 over the last 90 days. Company insiders own 5.63% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Natera by 32.3% in the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after buying an additional 207 shares during the period. Asset Management One Co. Ltd. acquired a new position in Natera in the first quarter valued at about $6,753,000. Golden State Wealth Management LLC increased its holdings in shares of Natera by 103.4% in the first quarter. Golden State Wealth Management LLC now owns 1,017 shares of the medical research company's stock worth $144,000 after acquiring an additional 517 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Natera during the first quarter worth about $1,640,000. Finally, Artemis Investment Management LLP raised its position in shares of Natera by 54.1% during the first quarter. Artemis Investment Management LLP now owns 198,778 shares of the medical research company's stock worth $28,109,000 after purchasing an additional 69,751 shares during the period. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.